查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1709466

肺纤维化生物标记市场，依生物标记类型、应用、最终用户、国家和地区划分－2025 年至 2032 年全球产业分析、市场规模、市场份额及预测

Pulmonary Fibrosis Biomarkers Market, By Type of Biomarkers, By Application, By End-user, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 301 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告重点

2024 年肺纤维化生物标记市场规模价值 42.9043 亿美元，2025 年至 2032 年的复合年增长率为 4.50%。

肺纤维化生物标记市场-市场动态

肺纤维化发生率的上升推动了对诊断生物标记的需求。

肺纤维化（PF）发生率的不断上升是生物标记市场成长的主要驱动力。在印度等国家，特发性肺纤维化 (IPF) 的盛行率正在上升，估计每 10 万人中有 14 至 43 人患有此病。病例数的不断增长凸显了早期准确诊断的迫切需求。一项研究显示，特发性肺纤维化 (IPF) 约占全国所有间质性肺病 (ILD) 的 17%，这强调了及早发现病情以有效控制的重要性。此外，浦那等地区的特发性肺纤维化病例每年增加 5-7%，这进一步凸显了对先进诊断工具的需求。随着全球肺纤维化病例持续上升，对能够诊断、监测病情进展和评估治疗效果的可靠生物标记的需求比以往任何时候都更加重要，从而推动了该市场对创新的需求。

肺纤维化生物标记市场—关键见解

根据我们的研究分析师的分析，预计全球市场在预测期内（2025-2032 年）的年复合成长率约为 4.50%。

根据生物标记类型的细分，预计诊断生物标记将在 2024 年占据最大市场份额

根据应用细分，诊断是 2024 年的主要应用

根据最终用户细分，诊断实验室是 2024 年领先的最终用户

按地区划分，北美是 2024 年最大的收入来源

肺纤维化生物标记市场-細項分析：

全球肺纤维化生物标记市场根据生物标记的类型、应用、最终用户和地区进行细分。

根据生物标记的类型，市场分为三类：诊断生物标记、预后生物标记、预测生物标记。诊断生物标记部分是肺纤维化生物标记市场中最突出和最重要的部分。早期准确诊断肺纤维化 (PF) 对于改善患者预后至关重要，而诊断生物标记在此过程中发挥着至关重要的作用。这些生物标记对于在早期阶段识别 PF 的存在至关重要，此时干预仍可减缓疾病进展。由于特发性肺纤维化 (IPF) 等疾病与其他肺部疾病相似，因此诊断起来具有挑战性，诊断生物标记有助于区分 PF 与其他疾病，从而实现更快、更准确的诊断。 KL-6、SP-D 和 CCL18 等生物标记在临床环境中越来越多地用于辅助诊断 IPF 和其他形式的肺纤维化。人们对 PF 的认识不断提高以及其在美国等地区的高发病率进一步加剧了对可靠诊断工具的需求。这种需求推动了新的、更有效的生物标记的研究和开发，确保诊断生物标记领域在市场上保持主导地位。

根据应用，市场分为三类：诊断、治疗监测、药物开发。诊断部分是肺纤维化生物标记市场中最重要的部分。早期准确诊断肺纤维化 (PF) 对于改善患者预后和及时治疗至关重要。由于 PF，特别是特发性肺纤维化 (IPF)，与其他肺部疾病具有相同的症状，因此经常被误诊，因此诊断生物标记对于将其与类似疾病区分开来至关重要。 KL-6、SP-D 和 CCL18 等生物标记通常用于临床实践，因为它们能够在早期阶段检测 PF，而此时干预措施对于减缓疾病进展最为有效。随着 PF 盛行率的上升，对精确诊断工具的需求也日益增加，从而推动了人们对开髮用于早期检测的新生物标记的关注。此外，由于研究机构和医疗保健提供者强调早期诊断，诊断应用仍然是肺纤维化生物标记市场成长和创新的核心。

肺纤维化生物标记市场—地理洞察

北美是肺纤维化生物标记市场的领先地区，因为它拥有先进的医疗保健基础设施、高发病率的肺部疾病以及正在进行的研究计划。尤其是美国，凭藉其顶级研究机构、製药公司以及越来越多的临床试验，占据了相当大的市场。美国约有 20 万人被诊断出患有特发性肺纤维化 (IPF)，因此迫切需要诊断生物标记来帮助早期发现和管理。此外，美国国立卫生研究院 (NIH) 等政府计画正在资助识别和验证生物标誌物的研究，以促进创新。该地区强大的医疗保健报销系统也确保新兴的生物标记被应用于临床实践。此外，人们对疾病的认识不断提高以及个人化医疗的进步进一步推动了市场的成长。

美国凭藉其先进的医疗保健体系和对医学研究的大量投资，在肺纤维化生物标记市场中占据主导地位。目前有超过 20 万人被诊断出患有特发性肺纤维化 (IPF)，对早期检测、预后和治疗监测的有效生物标记的需求正在迅速增长。

美国政府透过国立卫生研究院（NIH）等机构大力资助新生物标记的研究。这反过来又加速了 IPF 诊断工具和治疗方法的发展。该国还拥有强大的製药业，积极与研究机构合作，推动生物标誌物驱动的解决方案

肺纤维化生物标记市场-竞争格局：

肺纤维化生物标记市场的竞争格局以老牌製药巨头和专业生物技术公司的存在为标誌。基因泰克、罗氏和吉利德科学等主要公司凭藉其在肺部疾病领域的广泛研究能力和强大的产品组合占据了市场主导地位。

这些公司专注于推进生物标记的发现、进行临床试验以及将生物标记整合到治疗方案中。同时，Biodesix 和赛默飞世尔科技等规模较小的生物科技公司正在利用针对肺纤维化的创新生物标记平台和诊断工具取得重大进展。竞争环境也受到製药公司和研究机构之间策略合作的推动，旨在加速生物标记的验证和商业化。随着市场的发展，越来越多的公司采用个人化医疗方法，进一步加剧了竞争。

最新动态：

2023年10月，百时美施贵宝宣布，美国食品药物管理局（FDA）授予首创口服溶血磷脂酸受体1（LPA1）拮抗剂BMS-986278突破性疗法认定，用于治疗一种严重且危及生命的疾病－进行性肺纤维化（PPF）。这项头衔扩大了该公司的产品组合。

2020 年 3 月，百时美施贵宝与肺纤维化基金会 (PFF) 达成合作，以识别生物标记。此次合作旨在加速针对此难题的标靶疗法的开发，体现了该公司致力于改善患者治疗效果的承诺。这项措施有助于提高销售额和收入。

目录

第一章：肺纤维化生物标记市场概述

  • 研究范围
  • 市场估计年限

第二章：执行摘要

  • 市场片段
    • 肺纤维化生物标记市场片段（依生物标记类型）
    • 肺纤维化生物标记市场片段（依应用）
    • 肺纤维化生物标记市场片段（按最终用户）
    • 肺纤维化生物标记市场（按国家/地区）
    • 肺纤维化生物标记市场（按地区）
  • 竞争洞察

第三章：肺纤维化生物标记主要市场趋势

  • 肺纤维化生物标记市场驱动因素
    • 市场驱动因素的影响分析
  • 肺纤维化生物标记市场限制
    • 市场限制的影响分析
  • 肺纤维化生物标记市场机会
  • 肺纤维化生物标记市场未来趋势

第四章：肺纤维化生物标记产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第五章：肺纤维化生物标记市场：地缘政治紧张局势升级的影响

  • COVID-19 疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：肺纤维化生物标记市场格局

  • 2024年肺纤维化生物标记市场份额分析
  • 按主要製造商分類的细分数据
    • 成熟玩家分析
    • 新兴企业分析

第七章：肺纤维化生物标记市场－依生物标记类型

  • 概述
    • 按生物标誌物类型分類的细分市场份额分析
    • 诊断生物标记
    • 预后生物标记
    • 预测性生物标记

第 8 章：肺纤维化生物标记市场 - 按应用

  • 概述
    • 按应用细分市场占有率分析
    • 诊断
    • 治疗监测
    • 药物开发

第九章：肺纤维化生物标记市场－按最终用户

  • 概述
    • 按最终用户细分的份额分析
    • 医院和诊所
    • 诊断实验室
    • 研究与学术机构

第 10 章：肺纤维化生物标记市场 - 按地区

  • 介绍
    • 按地区分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美肺纤维化生物标记主要製造商
    • 北美市场规模及预测（按国家/地区）
    • 北美市场规模及预测（依生物标记类型）
    • 北美市场规模和预测（按应用）
    • 北美市场规模及预测（按最终用户）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲肺纤维化生物标记主要製造商
    • 欧洲市场规模及预测（按国家/地区）
    • 欧洲市场规模及预测（依生物标记类型）
    • 欧洲市场规模和预测，按应用
    • 欧洲市场规模及预测（按最终用户）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区肺纤维化生物标记主要製造商
    • 亚太地区市场规模及预测（依国家）
    • 亚太地区生物标记市场规模及预测
    • 亚太地区市场规模及预测（按应用）
    • 亚太地区市场规模及预测（依最终用户）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲肺纤维化生物标记主要製造商
    • 拉丁美洲市场规模及预测（按国家/地区）
    • 拉丁美洲市场规模及预测（依生物标记类型）
    • 拉丁美洲市场规模及预测（按应用）
    • 拉丁美洲市场规模及预测（按最终用户）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲（MEA）
    • 概述
    • 中东和非洲肺纤维化生物标记主要製造商
    • MEA 市场规模及预测（依国家/地区）
    • MEA 市场规模及预测（依生物标记类型）
    • MEA 市场规模及预测（按应用）
    • MEA 市场规模及预测（依最终用户）
    • 沙乌地阿拉伯
    • 阿联酋
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 其余地区

第 11 章：关键供应商分析-肺纤维化生物标记产业

  • 竞争仪錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司简介
    • Biodesix, Inc.
    • Genentech, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Bristol-Myers Squibb Company
    • AbbVie Inc.
    • Thermo Fisher Scientific Inc.
    • Abbott Laboratories
    • PerkinElmer, Inc.
    • Eli Lilly and Company
    • Gilead Sciences, Inc.
    • Novartis International AG
    • Johnson & Johnson
    • Mylan NV
    • Sanofi SA
    • Amgen Inc.

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4936

REPORT HIGHLIGHT

Pulmonary Fibrosis Biomarkers Market size was valued at US$ 4,290.43 Million in 2024, expanding at a CAGR of 4.50% from 2025 to 2032.

Pulmonary fibrosis biomarkers are biological indicators that help in the diagnosis, monitoring, and prognosis of pulmonary fibrosis, a progressive lung disease characterized by scarring of lung tissue. These biomarkers can be proteins, genes, or other molecules present in blood, urine, or tissue samples. They assist in understanding the disease's progression and response to treatment. Biomarkers such as KL-6, SP-D, and CCL18 are often used to monitor disease activity and predict outcomes. Research into pulmonary fibrosis biomarkers is crucial for early detection, personalized treatments, and the development of new therapies. These biomarkers also help differentiate pulmonary fibrosis from other lung diseases with similar symptoms. As the disease can be difficult to diagnose, biomarkers provide valuable insights for clinicians to make more accurate decisions. With ongoing studies, these biomarkers are increasingly seen as essential tools for better patient management.

Pulmonary Fibrosis Biomarkers Market- Market Dynamics

Rising incidence of pulmonary fibrosis drives demand for biomarkers in diagnosis.

The increasing incidence of pulmonary fibrosis (PF) is a key driver for the growth of the biomarkers market. In countries like India, the prevalence of idiopathic pulmonary fibrosis (IPF) is rising, with estimates ranging between 14 to 43 per 100,000 people. This growing number of cases highlights the urgent need for early and accurate diagnosis. A study revealed that IPF accounts for approximately 17% of all interstitial lung diseases (ILDs) in the country, emphasizing the importance of detecting the condition early to manage it effectively. Furthermore, regions like Pune have seen a 5-7% annual increase in IPF cases, which further underscores the demand for advanced diagnostic tools. As pulmonary fibrosis cases continue to rise globally, the need for reliable biomarkers that can diagnose, monitor disease progression, and assess treatment efficacy is more critical than ever, driving the demand for innovation in this market.

Pulmonary Fibrosis Biomarkers Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.50% over the forecast period (2025-2032)

Based on Type of Biomarkers segmentation, Diagnostic Biomarkers was predicted to show maximum market share in the year 2024

Based on application segmentation, Diagnosis was the leading application in 2024

Based on End-user segmentation, Diagnosis laboratories was the leading End-user in 2024

On the basis of region, North America was the leading revenue generator in 2024

Pulmonary Fibrosis Biomarkers Market- Segmentation Analysis:

The Global Pulmonary Fibrosis Biomarkers Market is segmented on the basis of Type of Biomarkers, Application, End-user, and Region.

The market is divided into three categories based on Type of Biomarkers: Diagnostic Biomarkers, Prognostic Biomarkers, Predictive Biomarkers. The Diagnostic Biomarkers segment is the most prominent and significant in the Pulmonary Fibrosis Biomarkers market. Early and accurate diagnosis of pulmonary fibrosis (PF) is crucial for improving patient outcomes, and diagnostic biomarkers play a vital role in this process. These biomarkers are essential in identifying the presence of PF at its early stages, when intervention can still slow disease progression. With diseases like idiopathic pulmonary fibrosis (IPF) being challenging to diagnose due to their similarities with other lung conditions, diagnostic biomarkers help differentiate PF from other diseases, leading to quicker and more accurate diagnoses. Biomarkers such as KL-6, SP-D, and CCL18 are increasingly being used in clinical settings to aid in diagnosing IPF and other forms of pulmonary fibrosis. The growing awareness of PF and its high incidence rate in regions like the U.S. further intensifies the need for reliable diagnostic tools. This demand is driving the research and development of new, more efficient biomarkers, ensuring that the diagnostic biomarkers segment remains dominant in the market.

The market is divided into three categories based on application: Diagnosis, Treatment Monitoring, Drug Development. The diagnosis segment is the most significant in the Pulmonary Fibrosis Biomarkers market. Early and accurate diagnosis of pulmonary fibrosis (PF) is crucial for improving patient outcomes and enabling timely treatments. Since PF, particularly idiopathic pulmonary fibrosis (IPF), shares symptoms with other lung diseases, it is often misdiagnosed, making diagnostic biomarkers vital for distinguishing it from similar conditions. Biomarkers such as KL-6, SP-D, and CCL18 are commonly used in clinical practice for their ability to detect PF at early stages, when interventions are most effective in slowing disease progression. With the rising prevalence of PF, there is an increasing demand for precise diagnostic tools, driving the focus on developing new biomarkers for early detection. Moreover, as research institutions and healthcare providers emphasize early diagnosis, the diagnostic application remains central to the growth and innovation in the pulmonary fibrosis biomarkers market.

Pulmonary Fibrosis Biomarkers Market- Geographical Insights

North America is a leading region in the Pulmonary Fibrosis Biomarkers market due to its advanced healthcare infrastructure, high prevalence of pulmonary diseases, and ongoing research initiatives. The United States, in particular, has a significant share in the market, supported by the presence of top-tier research institutions, pharmaceutical companies, and a growing number of clinical trials. With approximately 200,000 individuals diagnosed with idiopathic pulmonary fibrosis (IPF) in the U.S., there is a strong demand for diagnostic biomarkers to aid early detection and management. Furthermore, government programs, like the National Institutes of Health (NIH), are funding research to identify and validate biomarkers, boosting innovation. The region's strong healthcare reimbursement systems also ensure that emerging biomarkers are adopted into clinical practice. Additionally, rising awareness about the disease and advancements in personalized medicine are further propelling market growth.

The United States plays a dominant role in the Pulmonary Fibrosis Biomarkers market due to its advanced healthcare system and substantial investment in medical research. With over 200,000 individuals diagnosed with idiopathic pulmonary fibrosis (IPF), the demand for effective biomarkers for early detection, prognosis, and treatment monitoring is growing rapidly.

The U.S. government, through agencies like the National Institutes of Health (NIH), is heavily funding research to discover new biomarkers. This, in turn, accelerates the development of diagnostic tools and therapies for IPF. The country also boasts a robust pharmaceutical industry that actively collaborates with research institutions to advance biomarker-driven solutions

Pulmonary Fibrosis Biomarkers Market- Competitive Landscape:

The competitive landscape of the Pulmonary Fibrosis Biomarkers market is marked by the presence of both established pharmaceutical giants and specialized biotech companies. Major players like Genentech, F. Hoffmann-La Roche, and Gilead Sciences dominate the market due to their extensive research capabilities and robust portfolios in pulmonary diseases.

These companies focus on advancing biomarker discovery, conducting clinical trials, and integrating biomarkers into treatment protocols. At the same time, smaller biotech firms like Biodesix and Thermo Fisher Scientific are making significant strides with innovative biomarker platforms and diagnostic tools tailored for pulmonary fibrosis. The competitive environment is also driven by strategic collaborations between pharmaceutical companies and research institutions, aimed at accelerating biomarker validation and commercialization. As the market evolves, companies are increasingly adopting personalized medicine approaches, further intensifying competition.

Recent Developments:

In October 2023, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for BMS-986278, a first-in-class oral lysophosphatidic acid receptor 1 (LPA1) antagonist, for the treatment of progressive pulmonary fibrosis (PPF), a severe and life-threatening disease. This designation expanded the company's product portfolio.

In March 2020, Bristol Myers Squibb entered into a collaboration with the Pulmonary Fibrosis Foundation (PFF) to identify biomarkers. The partnership aimed to accelerate the development of targeted therapies for this challenging condition, reflecting the company's commitment to enhancing patient outcomes. This initiative helped boost sales and revenue.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Biodesix, Inc.
  • Genentech, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • Thermo Fisher Scientific Inc.
  • Abbott Laboratories
  • PerkinElmer, Inc.
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • Novartis International AG
  • Johnson & Johnson
  • Mylan N.V.
  • Sanofi S.A.
  • Amgen Inc.

GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET, BY TYPE OF BIOMARKERS- MARKET ANALYSIS, 2019 - 2032

  • Diagnostic Biomarkers
  • Prognostic Biomarkers
  • Predictive Biomarkers

GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Diagnosis
  • Treatment Monitoring
  • Drug Development

GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Research & Academic Institutions

GLOBAL PULMONARY FIBROSIS BIOMARKERS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Pulmonary Fibrosis Biomarkers Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Pulmonary Fibrosis Biomarkers Market Snippet by Type of Biomarkers
    • 2.1.2. Pulmonary Fibrosis Biomarkers Market Snippet by Application
    • 2.1.3. Pulmonary Fibrosis Biomarkers Market Snippet by End-user
    • 2.1.4. Pulmonary Fibrosis Biomarkers Market Snippet by Country
    • 2.1.5. Pulmonary Fibrosis Biomarkers Market Snippet by Region
  • 2.2. Competitive Insights

3. Pulmonary Fibrosis Biomarkers Key Market Trends

  • 3.1. Pulmonary Fibrosis Biomarkers Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Pulmonary Fibrosis Biomarkers Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Pulmonary Fibrosis Biomarkers Market Opportunities
  • 3.4. Pulmonary Fibrosis Biomarkers Market Future Trends

4. Pulmonary Fibrosis Biomarkers Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Pulmonary Fibrosis Biomarkers Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Pulmonary Fibrosis Biomarkers Market Landscape

  • 6.1. Pulmonary Fibrosis Biomarkers Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Pulmonary Fibrosis Biomarkers Market - By Type of Biomarkers

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type of Biomarkers, 2024 & 2032 (%)
    • 7.1.2. Diagnostic Biomarkers
    • 7.1.3. Prognostic Biomarkers
    • 7.1.4. Predictive Biomarkers

8. Pulmonary Fibrosis Biomarkers Market - By Application

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 8.1.2. Diagnosis
    • 8.1.3. Treatment Monitoring
    • 8.1.4. Drug Development

9. Pulmonary Fibrosis Biomarkers Market - By End-user

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-user, 2024 & 2032 (%)
    • 9.1.2. Hospitals & Clinics
    • 9.1.3. Diagnostic Laboratories
    • 9.1.4. Research & Academic Institutions

10. Pulmonary Fibrosis Biomarkers Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Pulmonary Fibrosis Biomarkers Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Pulmonary Fibrosis Biomarkers Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.8. UK
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. UK Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.3.8.4. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.8.5. UK Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.9. France
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. France Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.3.9.4. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.9.5. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.10. Italy
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. Italy Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.3.10.4. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.10.5. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.11. Spain
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. Spain Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.11.5. Spain Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.12. The Netherlands
      • 10.3.12.1. Overview
      • 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.3. The Netherlands Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.3.12.4. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.12.5. The Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Overview
      • 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.13.5. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.14. Russia
      • 10.3.14.1. Overview
      • 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.3. Russia Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.14.5. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Pulmonary Fibrosis Biomarkers Key Manufacturers in Asia Pacific
    • 10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. APAC Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
    • 10.4.5. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.6. APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.7. China
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. China Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.4.7.4. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.7.5. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.8. India
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. India Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.4.8.4. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.8.5. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.12. Indonesia
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Indonesia Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.13. Thailand
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Thailand Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.5. Latin America (LATAM)
    • 10.5.1. Overview
    • 10.5.2. Pulmonary Fibrosis Biomarkers Key Manufacturers in Latin America
    • 10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. LATAM Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
    • 10.5.5. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.5.6. LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa (MEA)
    • 10.6.1. Overview
    • 10.6.2. Pulmonary Fibrosis Biomarkers Key Manufacturers in Middle East and Africa
    • 10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. MEA Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
    • 10.6.5. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.6. MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.8. UAE
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. UAE Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.6.8.4. UAE Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.8.5. UAE Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type of Biomarkers, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Pulmonary Fibrosis Biomarkers Industry

  • 11.1. Competitive Dashboard
    • 11.1.1. Competitive Benchmarking
    • 11.1.2. Competitive Positioning
  • 11.2. Company Profiles
    • 11.2.1. Biodesix, Inc.
    • 11.2.2. Genentech, Inc.
    • 11.2.3. F. Hoffmann-La Roche Ltd.
    • 11.2.4. Bristol-Myers Squibb Company
    • 11.2.5. AbbVie Inc.
    • 11.2.6. Thermo Fisher Scientific Inc.
    • 11.2.7. Abbott Laboratories
    • 11.2.8. PerkinElmer, Inc.
    • 11.2.9. Eli Lilly and Company
    • 11.2.10. Gilead Sciences, Inc.
    • 11.2.11. Novartis International AG
    • 11.2.12. Johnson & Johnson
    • 11.2.13. Mylan N.V.
    • 11.2.14. Sanofi S.A.
    • 11.2.15. Amgen Inc.

12. 360 Degree AnalystView

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us